<SEC-DOCUMENT>0001161697-19-000273.txt : 20190627
<SEC-HEADER>0001161697-19-000273.hdr.sgml : 20190627
<ACCEPTANCE-DATETIME>20190627090645
ACCESSION NUMBER:		0001161697-19-000273
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20190627
DATE AS OF CHANGE:		20190627

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REPRO MED SYSTEMS INC
		CENTRAL INDEX KEY:			0000704440
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				133044880
		STATE OF INCORPORATION:			NY
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-229498
		FILM NUMBER:		19923063

	BUSINESS ADDRESS:	
		STREET 1:		24 CARPENTER RD
		CITY:			CHESTER
		STATE:			NY
		ZIP:			10918
		BUSINESS PHONE:		845-469-2042

	MAIL ADDRESS:	
		STREET 1:		24 CARPENTER RD
		CITY:			CHESTER
		STATE:			NY
		ZIP:			10918
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>prospectus_424b3-sup4.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT NO. 4 TO 424(B)(3)
<TEXT>
<HTML>
<HEAD>
</HEAD>
<TITLE></TITLE>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<DIV style="width:7.5in">
<BR>

<P style="margin:0px; font-size:12pt" align=right>Filed Pursuant to Rule 424(b)(3) </P>
<P style="margin:0px; font-size:12pt" align=right>Registration No. 333-229498</P>
<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>
<P style="margin:0px; font-size:12pt" align=center>PROSPECTUS SUPPLEMENT NO. 4</P>
<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>
<P style="margin:0px; font-size:12pt" align=center>(to Prospectus dated March 8, 2019)</P>
<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>
<P style="margin:0px; font-size:12pt" align=center>REPRO MED SYSTEMS, INC.</P>
<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>
<P style="margin:0px; font-size:12pt" align=center>11,101,697 shares of common stock</P>
<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>
<P style="margin:0px; font-size:12pt; text-align: justify">This prospectus supplement No. 4 supplements and amends the prospectus dated March 8, 2019, as supplemented
by prospectus supplement No. 1, dated April 29, 2019, as further supplemented by prospectus supplement No. 2, dated May 7, 2019
and prospectus supplement No. 3, dated May 8, 2019 (collectively, the &ldquo;Prospectus&rdquo;), which forms a part of our Registration
Statement on Form S-1 (Registration No. 333-229498). This prospectus supplement is being filed to update and supplement the information
in the Prospectus with information contained in our <A HREF="#form_8-K">Current Report on Form 8-K filed with the Securities and Exchange Commission on June 27, 2019</A> (the &ldquo;Current Report&rdquo;). Accordingly, we have attached the Current Report to this prospectus supplement.</P>
<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>
<P style="margin:0px; font-size:12pt; text-align: justify">The Prospectus and this prospectus supplement relate solely to 11,101,697 shares of REPRO MED SYSTEMS, INC. common stock, par value $0.01 per share, which we refer to as our common stock, which may be offered for sale from time to time by the stockholders named under the heading &ldquo;Selling Stockholders&rdquo; in the Prospectus.</P>
<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>
<P style="margin:0px; font-size:12pt; text-align: justify">This prospectus supplement should be read in conjunction with the Prospectus, including any supplements or amendments thereto. If there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. &nbsp;This prospectus supplement is not complete without, and may not be delivered or utilized except in connection with, the Prospectus, including any amendments or supplements to it.</P>
<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>
<P style="margin:0px; font-size:12pt; text-align: justify">Our common stock is currently listed on the OTCQX under the symbol &ldquo;REPR.&rdquo; The closing price of
our common stock as reported on the OTCQX on June 25, 2019, was $2.95.</P>
<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>
<P style="margin:0px; font-size:12pt; text-align: justify"><B>Investing in our common stock involves risks, and you should not invest unless you can afford to lose your entire investment. See the section entitled &ldquo;Risk Factors&rdquo; beginning on page 5 of the Prospectus. </B></P>
<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>
<P style="margin:0px; font-size:12pt; text-align: justify"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>
<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>
<P style="margin:0px; font-size:12pt" align=center><B>The date of this prospectus supplement is June 27, 2019.</B></P>
<P style="margin:0px"><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<HR noshade align="center" width="100%" size="2"><p style='page-break-before:always'></p><PAGE><BR>

<A NAME="form_8-K"></A>

<P style="margin:0" align=center><B>UNITED STATES</B></P>
<P style="margin:0" align=center><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
<P style="margin:0" align=center><B>Washington, DC 20549</B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; font-size:12pt" align=center><B>FORM 8-K</B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; font-size:12pt" align=center><B>CURRENT REPORT</B></P>
<P style="margin:0; font-size:12pt" align=center><B>Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0" align=center>Date of Report (Date of earliest event reported)&nbsp;&nbsp;&nbsp;<B><U>June 24, 2019</U></B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; font-size:14pt" align=center><B><U>REPRO MED SYSTEMS, INC.</U></B></P>
<P style="margin:0" align=center>(Exact name of registrant as specified in its charter)</P>
<P style="margin:0" align=center>&nbsp;</P>
<TABLE style="margin-top:0; font-size:10pt" cellpadding=0 cellspacing=0 align=center>
<TR><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center><B><U>New York</U></B></P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center><B><U>0-12305</U></B></P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center><B><U>13-3044880</U></B></P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center>(State or other jurisdiction<BR>
of incorporation)</P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center>(Commission<BR>
File Number)</P>
</TD><TD style="margin-top:0" valign=top width=240><P style="margin:0" align=center>(IRS Employer<BR>
Identification No.)</P>
</TD></TR>
</TABLE>
<P style="margin:0" align=center><BR></P>
<TABLE style="margin-top:0; font-size:10pt" cellpadding=0 cellspacing=0 align=center>
<TR><TD style="margin-top:0" valign=top width=288><P style="margin:0" align=center><B><U>24 Carpenter Road, Chester, New York</U></B></P>
</TD><TD style="margin-top:0" valign=top width=96><P style="margin:0" align=center><B><U>10918</U></B></P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top width=288><P style="margin:0" align=center>(Address of principal executive offices)</P>
</TD><TD style="margin-top:0" valign=top width=96><P style="margin:0" align=center>(Zip Code)</P>
</TD></TR>
</TABLE>
<P style="margin:0" align=center><BR></P>
<P style="margin:0" align=center>Registrant&rsquo;s telephone number, including area code&nbsp;&nbsp;&nbsp;<B><U>(845) 469-2042</U></B></P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0" align=center><U>not applicable</U></P>
<P style="margin:0" align=center>(Former name or former address, if changed since last report)</P>
<P style="margin:0" align=center>&nbsp;</P>
<P style="margin:0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">[ &nbsp;] &nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">Emerging growth company &nbsp;[_]</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &nbsp;[_]</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<P style="margin:0; text-align: justify">Securities registered pursuant to Section 12(b) of the Act:</P>
<P style="margin:0; text-align: justify">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="margin-top: 0px; font-size: 10pt"><TR height=0 style="font-size:1pt"><TD STYLE="width: 2.5in"></TD><TD STYLE="width: 2.5in"></TD><TD STYLE="width: 2.5in"></TD></TR>
<TR><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><U>Title of each class</U></P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><U>Trading symbol(s)</U></P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px"><U>Name of each exchange on which registered</U></P>
</TD></TR>
<TR><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px">common stock, $0.01 par value </P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px">REPR</P>
</TD><TD STYLE="margin-top: 0px; vertical-align: top"><P style="margin:0px">OTCQX</P>
</TD></TR>
</TABLE>
<P style="margin:0; text-align: justify">&nbsp;</P>

<HR noshade align="center" width="100%" size="2"><p style='page-break-before:always'></p><PAGE><BR>

<P style="margin:0"><B>ITEM 8.01 OTHER EVENTS.</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">As previously reported in the Company&rsquo;s reports filed under the Securities Exchange Act of 1934, as
amended, on June 25, 2015, EMED Technologies Corporation (&ldquo;EMED&rdquo;) filed a case in the United States District Court
for the Eastern District of Texas on June 25, 2015, claiming patent infringement on one of its patents by the Company&rsquo;s needle
sets, and seeking unspecified monetary damages (&ldquo;ED Texas &rsquo;476 matter&rdquo;). This case is one of several pending between RMS Medical and EMED.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">The Company is filing this Current Report on Form 8-K to report that, on June 24, 2019, the Texas Court Magistrate
Judge issued a Report and Recommendation decision with respect to the ED Texas &rsquo;476 matter finding no infringement, literally
or under the doctrine of equivalents, by the Company&rsquo;s accused products. On June 26, 2019, EMED filed objections to the decision.
Procedurally, all deadlines and pending motions are now suspended until the District Judge reviews the decision together with EMED&rsquo;s
objection and the briefing on the objections, and makes a final determination.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0px; text-align: justify">The Company believes it will prevail on the merits and the District Judge will uphold the decision of the
Magistrate Judge, although an adverse outcome in this matter could materially and adversely affect the Company&rsquo;s business,
financial condition, results of operations and cash flows.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">- 2 -</P>

<HR noshade align="center" width="100%" size="2"><p style='page-break-before:always'></p><PAGE><BR>

<P style="margin:0" align=center><B>SIGNATURES</B></P>
<P style="margin:0px; text-align: justify"><BR></P>
<P style="margin:0; text-indent:0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>
<P style="margin:0px; text-align: justify"><BR></P>
<TABLE style="margin-top:0; font-size:10pt" cellpadding=0 cellspacing=0 width=100%>
<TR><TD style="margin-top:0" valign=top><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=360 colspan=2><P style="margin:0">REPRO MED SYSTEMS, INC.<BR>
(Registrant)</P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=24><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=336><P style="margin:0">&nbsp;</P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top><P style="margin:0">Date: &nbsp;<U>June 27, 2019</U></P>
</TD><TD style="margin-top:0" valign=top width=24><P style="margin:0">By:</P>
</TD><TD style="margin-top:0" valign=top width=336><P style="margin:0"><U>/s/ Karen Fisher</U></P>
</TD></TR>
<TR><TD style="margin-top:0" valign=top colspan=2><P style="margin:0">&nbsp;</P>
</TD><TD style="margin-top:0" valign=top width=336><P style="margin:0">Karen Fisher<BR>
Chief Financial Officer</P>
</TD></TR>
</TABLE>
<P style="margin:0"><BR></P>
<P style="margin:0" align=center>- 3 -</P>

<HR noshade align="center" width="100%" size="2">
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
